ZBH.SW Zimmer Biomet (SIX) spikes to CHF67.50 pre-market 28 Jan 2026: monitor liquidity

ZBH.SW stock is trading at CHF67.50 pre-market on 28 Jan 2026 after a clear volume spike. Volume of 110 shares against an average of 3.00 implies a relative volume of 36.67x, signalling outsized interest in early trading. Price is down -4.26% from the previous close of CHF70.50 and sits at the year low of CHF67.50. We view this as a short-term liquidity event worth watching into upcoming earnings on 10 Feb 2026.

ZBH.SW stock: pre-market volume spike and price action

Trading shows a concentrated pre-market move. The stock opened at CHF67.50 and the day high and low match at CHF67.50, confirming the initial print. Volume is 110 versus an average of 3.00, a 36.67 times surge that fits the volume spike strategy. This spike coincides with one-day change -4.26%, suggesting sellers dominated the early trades.

Fundamentals and valuation snapshot for Zimmer Biomet Holdings, Inc.

Zimmer Biomet (ZBH.SW) reports EPS CHF3.19 and a trailing PE of 21.16. Market capitalisation is CHF13,377,254,963.00 with shares outstanding 198,181,555. Price to book is 1.37, price to sales is 2.18, and free cash flow yield is 7.63%. These figures show a mid‑cycle valuation versus medical device peers.

Technical snapshot and risk indicators

Momentum reads as oversold. RSI is 18.81, MACD is -0.07 with histogram -0.32, and ADX is 53.75 signalling a strong trend. Price sits below the 50‑day average CHF78.58 and the 200‑day average CHF87.90, which increases short‑term downside risk. Inventory and cash cycle metrics show operational pressure that can amplify volatility.

Meyka AI rating and model forecasts

Meyka AI rates ZBH.SW with a score out of 100. Meyka AI rates ZBH.SW with a score of 67.11/100, Grade B, suggestion HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects monthly CHF58.92, quarterly CHF90.29, and yearly CHF57.73. The quarterly projection implies an upside of 33.77% versus the current CHF67.50, while the yearly projection implies a downside of -14.47%. Forecasts are model-based projections and not guarantees.

Earnings calendar, catalysts and sector context

Earnings are scheduled for 10 Feb 2026 and will be the next major catalyst. The healthcare medical‑devices sector shows moderate strength year‑to‑date and average PE around 34.64 for the sector. Positive guidance or margin beats could reverse the pre‑market weakness. Conversely, weak guidance would likely widen this volume‑led move.

Trading strategy and liquidity notes

For volume spike traders we recommend monitoring order book depth and intraday VWAP. The extreme relative volume (36.67x) increases execution risk and slippage. If price holds above CHF67.50 on higher sustained volume, short‑covering could push price toward CHF75.00 as initial resistance. Use tight risk limits and expect higher intraday volatility.

Final Thoughts

The immediate fact is the pre‑market volume spike in ZBH.SW stock at CHF67.50 on 28 Jan 2026, with volume 110 versus an average 3.00. That relative volume of 36.67x makes this a clear short‑term liquidity event. Fundamentals show EPS CHF3.19 and PE 21.16, with free cash flow yield 7.63% and price to book 1.37, positioning the company in a reasonable valuation band for medical devices. Meyka AI’s model projects a quarterly target of CHF90.29 (+33.77%) and a yearly target of CHF57.73 (-14.47%), underlining forecast dispersion. For active traders we advise watching sustained volume and the order book into the 10 Feb 2026 earnings release. Long‑term investors should weigh valuation, debt metrics and product cycle before adding exposure. Meyka AI provides this analysis as an AI‑powered market analysis platform and not as investment advice. Sources: Zimmer Biomet investors and Meyka stock page.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.